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ABSTRACT
Objective: To examine the relationship between 2markers of early multiple sclerosis (MS) onset, 1
genetic (HLA-DRB1*1501) and 1 experiential (early menarche), in 2 cohorts.
Methods: We included 540 white women with MS or clinically isolated syndrome (N 5 156 with
genetic data available) and 1,390 white women without MS but with a first-degree relative with
MS (Genes and Environment in Multiple Sclerosis [GEMS]). Age at menarche, HLA-DRB1*1501
status, and age at MS onset were analyzed.
Results: In both cohorts, participants with at least 1 HLA-DRB1*1501 allele had a later age at
menarche than did participants with no risk alleles (MS: mean difference5 0.49, 95% confidence
interval [CI] 5 [0.03–0.95], p 5 0.036; GEMS: mean difference 5 0.159, 95% CI 5 [0.012–
0.305], p 5 0.034). This association remained after we adjusted for body mass index at age 18
(available in GEMS) and for other MS risk alleles, as well as a single nucleotide polymorphism near
the HLA-A region previously associated with age of menarche (available in MS cohort). Confirming
previously reported associations, in our MS cohort, every year decrease in age at menarche was
associated with a 0.65-year earlier MS onset (95% CI 5 [0.07–1.22], p 5 0.027, N 5 540).
Earlier MS onset was also found in individuals with at least 1 HLA-DRB1*1501 risk allele (mean
difference 5 23.40 years, 95% CI 5 [26.42 to 20.37], p 5 0.028, N 5 156).
Conclusions: In 2 cohorts, a genetic marker for earlier MS onset (HLA-DRB1*1501) was inversely
related to earlier menarche, an experiential marker for earlier symptom onset. This finding war-
rants broader investigations into the association between the HLA region and hormonal regula-
tion in determining the onset of autoimmune disease. Neurol Genet 2016;2:e88; doi: 10.1212/
NXG.0000000000000088
GLOSSARY
BMI 5 body mass index; CI 5 confidence interval; CIS 5 clinically isolated syndrome; EDSS 5 Expanded Disability Status
Scale; GEMS 5 Genes and Environment in Multiple Sclerosis; GRS 5 genetic risk score; GWAS 5 genome-wide association
study; HLA 5 human leukocyte antigen; LD 5 linkage disequilibrium; MS 5 multiple sclerosis; SNP 5 single nucleotide
polymorphism.
Understanding the cumulative effect of to-date disparate genetic and experiential risk factors on
multiple sclerosis (MS) onset and course may be key to our ability to eventually predict and pre-
vent the onset of clinical symptoms.1 The HLA-DRB1*1501 MS susceptibility allele has been
previously associated with earlier age at MS onset.2–4 Across an individual’s life history, the
adolescent period may represent a critical window during which environmental factors modulate
MS risk or age at onset.5 Among these, earlier menarche, a risk factor MS,6–8 has been tied with
earlier onset of MS symptoms,9 although not always.6 Previous studies have sought to integrate
genetic and experiential risk factors, for example, uncovering a striking interaction between
obesity and HLA-DRB1*1501 in determining MS risk.10
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In the current study, we tested the association
between HLA-DRB1*1501 and early menarche
in 2 cohorts of white women, one with and one
without MS. Secondarily, we confirmed the
association between each marker and age at first
MS symptoms in the cohort of affected women.
METHODS Participants. Individuals with MS. These par-
ticipants were patients of the Partners Multiple Sclerosis Center,
aged 18 or above, enrolled in the Comprehensive Longitudinal
Investigation of Multiple Sclerosis at the Brigham and Women’s
Hospital (CLIMB, www.climbstudy.org).11 Female participants
were included in this study if they met the diagnostic criteria of
relapsing remitting MS by the 2005 McDonald criteria12 or of
clinically isolated syndrome (CIS).
Reproductive variables. A reproductive questionnaire, which is
deployed to all active female CLIMB participants with a diagnosis
of MS or CIS, was analyzed after a 60% response rate was achieved
(on June 20, 2014), as reported previously.13 Among these 724
respondents, 675 provided an age at menarche. Participants with
menarche data were older at first MS symptom than the 486 non-
respondents and participants without menarche data (33.8 vs 32.6
years, p , 0.05), but the groups did not differ in race, ethnicity,
disease category, or Expanded Disability Status Scale (EDSS)14 at
the most recent visit (p . 0.05 for each). The questionnaire var-
iables included in the current analysis were (1) reported age at
menarche and (2) response to whether a participant had “been told
you were obese” during childhood and/or adolescence (yes/no).
Clinical data. Reproductive questionnaire responses were linked
to demographic and clinical data available through CLIMB. Of
the 675 participants who provided age at menarche and response
to childhood obesity question in the reproductive questionnaire,
we identified 540 participants for whom information about (3)
residency at age 15 (north/middle/south United States; allowing
us to categorize the latitude of residency at age 15 as a proxy for
vitamin D exposure) and (4) smoking history (ever smoker/never
smoker) was available. Of the 540 participants identified, 156 had
genetic data available (see below, and table 1).
Individuals with family history of MS. The 1,390 partici-
pants without MS were adult female participants in the Genes
and Environment in Multiple Sclerosis (GEMS) study. This pro-
spective cohort study was designed to map the sequence of events
in the transition from health to MS, by enrolling individuals who
have a first-degree relative with a diagnosis of MS.1 At study
enrollment, participants complete a detailed demographic, health,
and reproductive questionnaire and provide samples for genetic
analyses. GEMS participants were excluded from the current
study if they themselves carried a diagnosis of MS.
Genotyping and genetic risk score. Genotyping of the indi-
viduals with MS15 and GEMS participants1 has been described
previously. A genetic risk score (GRS) was designed from a list of
64 validated and replicated single nucleotide polymorphisms
(SNPs) that are associated with MS susceptibility2,16 and was the
most up-to-date list as of 2011 when targeted genotyping of GEMS
participants first began.1 This list of 64 SNPs included 5 within the
major histocompatibility complex or human leukocyte antigen
(HLA) region (table e-1 at Neurology.org/ng). Each SNP was
coded additively by the established risk allele and weighted by
the natural log of the published odds ratio for MS susceptibility.
The GRS59 refers to the GRS64 without the 5 HLA SNPs.
Standard protocol approvals, registrations, and patient
consents. Institutional Review Board approval was granted by
the Partners Human Research Committee.
Statistical analysis. All analyses were conducted using the Sta-
tistical Analysis System (SAS) 9.3 (Cary, NC). Given the low
number of non-white participants (,7%), to mitigate the
possible role of ancestry in genetic associations,4,17 only white
participants (fewer than 5% of whom identified as Hispanic)
were included in this study. We compared the GEMS and MS
genetic cohorts, as well as the MS participants with and without
genetic data, using a 2-sample t test for continuous variables (ages,
GRS), Fisher exact test for disease category, and 2-tailed Mann-
Whitney U test for EDSS.
In our MS cohort, we first confirmed that the previously re-
ported association between both age at menarche and genetic risk
markers, and age at first symptoms, was present. To do this, we
performed univariate analysis using a simple linear regression
between each predictor (age at menarche, HLA alleles, GRS64,
and GRS59) and age at first symptoms. We selected the
rs3129889 SNP as our primary SNP, because it refers to the
HLA-DRB1*1501 MS susceptibility allele, which has been pre-
viously associated with earlier age at disease onset.2–4 We exam-
ined SNPs in 2 ways; we report analyses examining SNPs as
a categorical variable (at least 1 susceptibility allele vs none) using
a 2-sample t test; the results were similar when we analyzed alleles
as continuous variables (i.e., 0, 1, and 2; table e-2) using a linear
regression model. We further assessed the potential confounding
effect of reported obesity, latitude of residency at age 15, and
smoking history, by including these variables in a multivariate
analysis (multiple linear regression) for each of the models.
Then, in our primary analysis, we assessed the association
between genetic risk markers (HLA alleles, GRS64 and
GRS59) and age at menarche in both cohorts using multiple lin-
ear regression models. Here again, the rs3129889 SNP was our
primary SNP. Because 1 HLA-A allele has previously been found
to be associated with menarcheal age in a large genome-wide asso-
ciation study (GWAS) through the rs16896742 SNP, which is
near HLA-A,18 we further adjusted our analyses for rs16896742
(available in theMS cohort). Finally, we also adjusted for reported
body mass index (BMI) at age 18 (available in the GEMS cohort).
Table 1 Demographic and genetic characteristics of women with (CLIMB
cohort) and without (GEMS cohort) multiple sclerosis
Cohort
Discovery:
Participants with MS
Replication:
Participants without MS
CLIMB Study (N 5 156) GEMS Study (N 5 1,390)
Age at menarche, y, SD (range) 12.6 (1.5–8.0) 12.7 (1.4–8.0)
Age at survey,a y, SD (range) 50.6 (10.1–50.6) 34.0 (8.4–33.0)
HLA-DRB1*1501 (rs3129889_G),
n (%)a
0 75 (48.1) 843 (60.6)
1 72 (46.2) 497 (35.8)
2 9 (5.8) 50 (3.6)
GRS 64, mean (SD, range)a 10.1 (0.9–4.6) 9.9 (0.9–6.5)
GRS 59, mean (SD, range)a 7.8 (0.6–2.9) 7.7 (0.6–4.1)
Abbreviations: GEMS 5 Genes and Environment in Multiple Sclerosis; GRS 5 calculated
genetic risk score; IQR 5 interquartile range; MS 5 multiple sclerosis.
ap , 0.05.
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RESULTS Demographic and disease characteristics. In
our 2 cohorts of women, age at menarche was similar
(12.6 and 12.7). As expected, the 156 women with
MS had a higher GRS64 and GRS59 and were more
likely to carry an HLA-DRB1*1501 risk allele, than
were the 1,390 women in the GEMS cohort. The MS
women also seemed to be older than the women
without MS (table 1). Among the participants with
MS, the 156 participants with genetic data available
did not differ from the 384 participants without
genetic data in terms of age at menarche (2-tailed
t 5 20.60; 95% confidence interval [CI] 5
[20.35 to 0.18]; p 5 0.55), age at first symptom
(2-tailed t 5 1.19; 95% CI 5 [20.71 to 2.88];
p 5 0.23), or EDSS at last visit (Mann-Whitney U
test5 31; p5 0.11). However, there were no women
with CIS among the genotyped population, likely
reflecting inclusion criteria for genotyping (table 2).
Age at first symptoms. First, we confirmed that both
the HLA-DRB1*1501 risk allele and age at menarche
were associated with earlier age at first MS symptoms
in our cohort of affected women (CLIMB). The pres-
ence of at least 1HLA-DRB1*1501 allele was associated
with earlier age at first symptoms (mean difference 5
23.40, 95% CI 5 [26.42 to 20.37], p 5 0.028,
N 5 156). No association was found between any of
the other 4 HLA alleles, or the overall genetic risk score
GRS 64, and age at first symptoms (p. 0.10 for each).
Earlier age at menarche was also associated with
earlier age at first MS symptom (figure 1). Specifi-
cally, the mean age at first symptoms was increased by
0.65 years for every 1-year increase in age at menarche
(mean 5 0.65; 95% CI 5 [0.07–1.22], p 5 0.027,
N5 540). This association remained (mean 5 0.63;
95% CI5 [0.05–1.21], p5 0.033) after we adjusted
for 3 potential confounders (latitude at age 15,
smoking history at first symptom, and obesity status
in childhood or adolescence), none of which was sig-
nificant in the multivariate model (p . 0.05 for
each). Then, we ensured that the associations
observed in the entire cohort were similar in the sub-
set of participants with genetic data. We still observed
that age at MS onset increased with increasing age at
menarche, adjusting for the potential confounders.
Specifically, for every 1-year increase in the age at
menarche, the mean age at first symptoms increased
by 0.35; but in the reduced sample of participants, this
association was no longer significant (mean 5 0.35;
95% CI 5 [20.69 to 1.39]; p 5 0.51; n 5 156).
Genetic risk and age at menarche in 2 cohorts. Because
both earlier menarche and genetic risk have previ-
ously been associated with earlier age at first symp-
toms, we sought to understand the association
between menarche and genetic risk. Surprisingly, in
our discovery cohort of women with MS, participants
with at least 1 HLA-DRB1*1501 allele had a later age
at menarche than participants with no risk alleles (2-
tailed t 5 2.12, 95% CI 5 [0.03–0.95]; p 5 0.036;
table 3). In the replication cohort of individuals
without MS but with at least 1 first-degree relative
with MS (GEMS), this was also true (2-tailed t 5
2.15, 95% CI 5 [0.01–0.31], p 5 0.032; table 3).
When we combined the discovery and replication
cohorts, having at least 1 HLA-DRB1*1501 risk
allele was associated with a later age at menarche (2-
tailed t5 2.69, 95% CI5 [0.05–0.33]; p5 0.007).
When the cohort effect was accounted for as
a categorical variable in the regression model, our
results remain unchanged (mean difference 5 0.17;
95% CI 5 [0.04–0.31]; p 5 0.011).
When we examined other genetic markers, a high-
er GRS64 score was also associated with later age at
Table 2 Demographic and disease characteristics of 540 white female participants with multiple sclerosis
(CLIMB Study)
Participants
with complete
covariate data (N 5 540)
Participants
without genetics
data (n 5 384)
Participants
with genetics
information (n 5 156)
Age at menarche, mean (SD; range) 12.6 (1.4; 9.0–17.0) 12.6 (1.4; 9.0–17.0) 12.6 (1.5; 9.0–17.0)
Age at first symptom, mean (SD; range) 33.6 (9.6; 11.5–64.6) 33.9 (9.64; 11.5–64.6) 32.83 (9.6; 13.5–56.5)
Disease category at last visit, n (%)a
Clinically isolated syndrome 27 (5.0) 27 (7.0) 0 (0.0)
Primary progressive MS 12 (2.2) 11 (2.9) 1 (0.6)
Progressive relapsing MS 4 (0.7) 2 (0.5) 2 (1.3)
Relapsing-remitting MS 419 (77.6) 289 (75.3) 130 (83.3)
Secondary progressive MS 78 (14.4) 55 (14.3) 23 (14.7)
EDSS at last visit, median (IQR; range) 1.5 (1.5; 0.0–9.5) 1.5 (3.0; 0.0–8.0) 1.5 (1.5; 0.0–9.5)
Abbreviations: EDSS 5 Expanded Disability Status Scale; IQR 5 interquartile range; MS 5 multiple sclerosis.
ap , 0.05.
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menarche in the individual and combined cohorts
(p , 0.05, table 3). However, this was likely driven
by the HLA-DRB1*1501 allele because there was no
association between any of the other HLA alleles, or
of the GRS59 (GRS64 without HLA SNPs), and age
at menarche in either cohort (p . 0.10 for each
analysis). In sensitivity analyses, we addressed the
possibility that the HLA-DRB1*1501 effect was
driven, through linkage disequilibrium (LD), by
another SNP, namely, an HLA-A allele previously
found to be associated with menarcheal age in a large
GWAS (through the proxy rs16896742 SNP18).
When we further adjusted our analyses for
rs16896742 in the MS cohort, the association
between HLA-DRB1*1501 and later menarcheal
age remained (mean 5 0.49, 95% CI 5 [0.03–
0.95], p 5 0.037).
In addition, in the GEMS cohort, for whom
BMI at age 18 was available, with higher BMI itself
associated with earlier age at menarche (mean differ-
ence 5 20.07 years; 95% CI 5 [20.08 to
20.05]; p , 0.0001, N 5 1,388), adjusting for
BMI at age 18 did not change the significance of
the association between HLA-DRB1*1501 and age
at menarche (mean difference 5 0.1538; 95%
CI 5 [0.029–0.278]; p 5 0.015; N 5 1,388).
Summary of associations. Altogether, a summary of the
directionality of the findings between HLA-
DRB1*1501, age at menarche, and age at first symp-
toms is represented in figure 2.
DISCUSSION In this analysis of a well-phenotyped
cohort of women with MS, both earlier age at
menarche and an established genetic risk factor for
Figure 1 Earlier age at menarche is associated with earlier age at first
symptoms
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MS, HLA-DRB1*1501 status, were associated with
earlier onset of MS symptoms. However, when we
examined the association between HLA-DRB1*1501
status and age at menarche, in both a cohort of
women at increased genetic risk for MS and our
clinical cohort, this risk allele was associated with
a later age at menarche.
The age at menarche has been decreasing over the
past decades, and downstream events associated with
earlier reproductive maturation have been hypothe-
sized as one mechanism explaining an apparent
increase in the female:male sex ratio in MS.19 Our
first observation, of an association between earlier
menarche and earlier age at MS symptoms, adds to
the growing literature about the role of changes at
puberty in the development of MS risk.5,6,9,20 Mech-
anistically, it is possible that this association is
causal, through an effect of cycling gonadal hor-
mones on immune regulation, inflammatory events,
and ongoing neuronal development and susceptibil-
ity. This is supported by a recent report of increasing
relapses as adolescent girls transition through
puberty.21 However, it is also possible that earlier
menarche merely reflects an earlier adipose, proin-
flammatory childhood, and adolescent environment.
There is an established link between adiposity and
earlier menarche in healthy girls,22,23 and many
genes involved in the regulation of adiposity are also
associated with timing of menarche.24,25 An associa-
tion between adolescent obesity and MS risk, first
reported in the Nurses’ Health Study,26 has been
replicated for both adult-onset27,28 and childhood-
onset MS29; and recently, higher adolescent BMI has
also been associated with earlier age of MS onset.30
The role for adiposity-related inflammatory mecha-
nisms is supported by elevated adiposity markers
such as leptin reported in MS,31,32 as well as striking
interactions between adolescent obesity and HLA
risk genes in predicting adult-onset MS.10
Given such previous reports of synergistic associa-
tions between genetic and experiential factors in
determining MS risk,10 we asked whether established
MS genetic risk alleles, previously found to be asso-
ciated with age of MS onset (for both HLA-DRB12–4
and broader genetic risk variants33,34), might underlie
or enhance the association between menarcheal age
and age of MS onset. We found a statistical trend
between genetic risk factors for MS and earlier age
at MS first symptoms, consistent with one previous
report.9 Because there was no association between
menarcheal age and age at MS onset in another large
study,6 further cohorts are required to validate our
observations and to assess the role of regional or
epochal differences in menarcheal age and delay in
MS diagnosis. Although the association between
menarcheal age and symptom onset was expected, it
was unexpected that an MS risk allele would show an
association with later (rather than earlier) menarcheal
age. The presence of HLA-DRB1*1501 was associ-
ated with later age at menarche, which in turn is
associated with later age at MS onset.
There are few previous reports linking HLA alleles
and menarcheal age.35 Given the recognized extent of
LD in the HLA region on chromosome 6,36 one pos-
sible explanation for our finding might be that an
allele in LD with HLA-DRB1*1501 might drive the
apparent association between HLA-DRB1*1501
(which is in this scenario neutral) and later menar-
cheal age, even as other environmental factors are
driving a relationship between earlier menarche and
MS risk. However, we found no evidence that the
other MS HLA risk alleles included in our GRS, or
that an SNP near the HLA-A region previously found
to show a genome-wide association with age of men-
arche,18 mitigated the association between HLA-
DRB1*1501 and menarcheal age. Our findings hint
at previously unexplored associations between
immune regulation and pubertal timing, warranting
not only replication in other data sets but also clari-
fication of whether HLA-DRB1*1501 or an allele in
LD with HLA-DRB1*1501 is driving the association
with menarcheal age, as well as mechanistic explora-
tions of the genetic and epigenetic regulation of
immune activity during the pubertal transition.
The largest limitation of this study was that adi-
posity during the adolescent years was only incom-
pletely captured for the MS participants; however,
in the GEMS cohort, we were able to verify that
the association between HLA status and menarcheal
age was not influenced by BMI at age 18. The second
limitation was the statistically significant, but minor
in absolute terms, respondent biases in the reproduc-
tive survey. If respondents were older at MS onset
than nonrespondents, they may have been less likely
to have early menarche and to carry HLA-DRB*1501
Figure 2 Flow diagram depicting the interaction between HLA risk allele,
menarche, and age at first symptoms in female patients with multiple
sclerosis
Presence of HLA-DRB1*1501 multiple sclerosis risk allele is associated with later age at
menarche, which in turn is associated with later age at first symptoms. Presence of the HLA-
DRB1*1501 risk allele is associated with earlier age at first symptoms. A significant asso-
ciation/difference (p , 0.05) is represented by an asterisk (*). A positive association is
represented by a plus sign (1) and a negative association by a negative sign (2).
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risk allele; it is possible that with a higher response
rate, we would have observed even stronger associa-
tions between genetic risk and menarcheal age. Third,
only a subset of our participants had genetic data
available for analysis, limiting the interpretability of
data in the wider cohort of women and for women
who are not white.
The findings in this study lend complexity to the
analysis of early risk factors for MS onset, suggesting
a more complex interplay between genetic risk factors
and hormonal exposures in the development of
inflammatory disease.
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